Indications et traitement de la dégénérescence maculaire liée à l'âge (DMLA) en pratique (notice n° 1006602)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04806cam a2200409 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250125135510.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Gicquel, Marie-Claude Cabanel |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Indications et traitement de la dégénérescence maculaire liée à l'âge (DMLA) en pratique |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2013.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 81 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Objectif?: décrire et analyser les pratiques diagnostiques et thérapeutiques en matière de dégénérescence maculaire liée à l’âge (DMLA) au regard des référentiels en vigueur. Méthodes?: constitution d’un échantillon multirégional de patients relevant du RSI (artisans, commerçants, professions libérales) atteints de DMLA confirmée et ayant bénéficié d’un premier remboursement de vertéporfine (Visudyne®), pégaptanib (Macugen®) et/ou ranibizumab (Lucentis®) en 2008. Recueil rétrospectif des données par le médecin-conseil auprès de l’ophtalmologiste. Comparaison des traitements dispensés aux autorisations de mise sur le marché (AMM) pour les médicaments concernés et à leurs fiches d’information thérapeutique (FIT), plus restrictives et encadrant la prise en charge par l’Assurance maladie. Étude des examens complémentaires réalisés en fonction des recommandations de la Haute Autorité de santé (HAS). Résultats?: l’échantillon était composé de 184 patients. Lucentis® était présent dans 91,8 % des protocoles. Au regard des critères inscrits dans les FIT, les néovaisseaux choroïdiens rétro-fovéolaires étaient présents pour 62,0 % des prescriptions de Lucentis® à l’instauration du traitement et l’acuité visuelle répondait aux valeurs préconisées pour 83,5 % des patients. L’angiographie à la fluorescéine, obligatoire selon la HAS pour l’instauration du traitement, était réalisée chez 87,5 % des patients. Conclusion?: les constats de divergence de la pratique par rapport aux référentiels reposaient principalement sur une étendue de l’utilisation de Lucentis® au-delà des indications thérapeutiques remboursables par l’Assurance maladie. Ils laissaient apparaître une inadéquation du prix au regard du volume des ventes estimé selon les référentiels, inadéquation qui pourrait être majorée par l’extension récente de ses indications thérapeutiques remboursables. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The treatment of age-related macular degeneration (AMD) in practice Aim: The purpose of this paper is to describe and analyze the diagnosis and treatment of age-related macular degeneration (AMD) based on current guidelines. Methods: A study was conducted on a sample of French AMD patients covered by the RSI (public health insurance for self-employed workers), who received a first reimbursement in 2008 for treatments including verteporfin (Visudyne®), pegaptanib (Macugen®) and/or ranibizumab (Lucentis®). Data were collected retrospectively from the ophthalmologist by the medical adviser.Treatments were compared with the marketing authorisation for AMD drugs and therapeutic indications.Complementary examinations were also examined based on the recommendations of the Haute Autorité de Santé (HAS). Results: 184 patients were included in the sample. Lucentis® was used in 91.8% of cases.62.0% of the patients treated with Lucentis® had subfoveal CNV. Visual acuity was good in 83.5% of cases.Fluorescein angiography (recommended by the HAS before treatment initiation) was performed in 87.5% of cases. Conclusion: The gap between guidelines and practice is illustrated by the case of Lucentis®, which is increasingly used for indications other than those reimbursed by health insurance. The findings indicate that the current price does not reflect sales volume estimates based on current guidelines, a problem that may be compounded by the recent extension of indications covered by health insurance. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ranibizumab |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | dégénérescence maculaire liée à l'âge |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anticorps monoclonaux |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | vertéporfine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | régime social des indépendants |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ranibizumab |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | macular degeneration |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | age-related |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | monoclonal |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | AMD |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | antibodies |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | regime social des indépendants |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | verteporfin |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tanguy, Maëla |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Apicella, Christophe |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Charvier, Marianne |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Clavaud, Henri |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lescarret, Bruno |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Neme, Brigitte |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Perrot, Pascal |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Santé Publique | 25 | 3 | 2013-07-22 | p. 315-324 | 0995-3914 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-sante-publique-2013-3-page-315?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-sante-publique-2013-3-page-315?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux